JP2021523945A5 - - Google Patents

Info

Publication number
JP2021523945A5
JP2021523945A5 JP2021514456A JP2021514456A JP2021523945A5 JP 2021523945 A5 JP2021523945 A5 JP 2021523945A5 JP 2021514456 A JP2021514456 A JP 2021514456A JP 2021514456 A JP2021514456 A JP 2021514456A JP 2021523945 A5 JP2021523945 A5 JP 2021523945A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
composition according
optionally
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514456A
Other languages
English (en)
Japanese (ja)
Other versions
JP7644000B2 (ja
JP2021523945A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/050462 external-priority patent/WO2019218015A1/en
Publication of JP2021523945A publication Critical patent/JP2021523945A/ja
Publication of JP2021523945A5 publication Critical patent/JP2021523945A5/ja
Application granted granted Critical
Publication of JP7644000B2 publication Critical patent/JP7644000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514456A 2018-05-15 2019-05-15 活性化剤 Active JP7644000B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901672A AU2018901672A0 (en) 2018-05-15 Activating Agents
AU2018901672 2018-05-15
PCT/AU2019/050462 WO2019218015A1 (en) 2018-05-15 2019-05-15 Activating agents

Publications (3)

Publication Number Publication Date
JP2021523945A JP2021523945A (ja) 2021-09-09
JP2021523945A5 true JP2021523945A5 (enExample) 2022-05-24
JP7644000B2 JP7644000B2 (ja) 2025-03-11

Family

ID=68539125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514456A Active JP7644000B2 (ja) 2018-05-15 2019-05-15 活性化剤

Country Status (8)

Country Link
US (2) US12134663B2 (enExample)
EP (1) EP3794015A4 (enExample)
JP (1) JP7644000B2 (enExample)
KR (1) KR20210021311A (enExample)
CN (1) CN112368293A (enExample)
AU (1) AU2019268411B2 (enExample)
CA (1) CA3100072A1 (enExample)
WO (1) WO2019218015A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7386852B2 (ja) 2018-05-15 2023-11-27 インテルク ペプチド セラピューティクス リミテッド ペプチド活性化剤
KR20210097729A (ko) * 2018-11-30 2021-08-09 인터크 펩타이드 테라퓨틱스 리미티드 피부 병태를 개선하기 위한 폴리펩타이드 및 방법
EP4244234A4 (en) * 2020-11-10 2024-12-25 InterK Peptide Therapeutics Limited POLYPEPTIDES AND METHODS FOR IMPROVING SKIN DISEASES
WO2023019323A1 (en) * 2021-08-20 2023-02-23 Interk Peptide Therapeutics Limited Compositions and methods for treating autoimmunity, including autoimmunity associated with cancer and cancer therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
US20030162956A1 (en) 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
PT1446489E (pt) 2001-10-15 2012-04-24 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas, como vectores para a transferência de adn e terapia genética in vitro e in vivo
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
WO2005030258A2 (en) 2003-09-22 2005-04-07 Acidophil Llc Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US20060194319A1 (en) 2004-09-02 2006-08-31 Webb Carol F Promoter substitution for immunoglobulin therapy
WO2006029981A1 (en) 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
WO2006031996A2 (en) 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
DK2185698T3 (en) * 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
KR101294514B1 (ko) * 2007-09-18 2013-08-12 가부시키가이샤 그린 펩티드 Ctl 유도제 조성물
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
US9327008B2 (en) * 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
AU2010215086A1 (en) 2009-02-23 2011-09-08 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
WO2012174412A2 (en) 2011-06-16 2012-12-20 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
WO2013033838A1 (en) 2011-09-09 2013-03-14 Pharmagap Inc. Liposomal formulations of cationic peptides and uses thereof
CN104271590B (zh) * 2012-01-24 2018-06-05 Inter-K私人有限公司 用于癌治疗的肽剂
WO2015053338A1 (ja) * 2013-10-08 2015-04-16 学校法人東京理科大学 カチオン性ペプチドおよびそれを含む医薬組成物
JP6367600B2 (ja) 2014-04-18 2018-08-01 矢崎総業株式会社 コネクタ
WO2018226992A1 (en) * 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors

Similar Documents

Publication Publication Date Title
JP7360419B2 (ja) 安定化抗微生物性ペプチド
JP2014521684A5 (enExample)
JP2021100937A5 (enExample)
JP2013500990A5 (enExample)
JP2008514586A5 (enExample)
RU2016110153A (ru) Новые пептиды и их аналоги для применения при лечении мукозита полости рта
RU2014140231A (ru) Антимикробные пептиды
JP2009534451A5 (enExample)
US20250215054A1 (en) Compositions and methods for treatment of fungal infections
JP2021523946A5 (enExample)
JPWO2022202816A5 (enExample)
HUT61036A (en) Process for producing new polypeptides capable of linking to lipopolysaccharides and pharmaceutical compositions comprising same as active ingredients
CN109232744A (zh) 改进型齐考诺肽
JP2017500849A5 (enExample)
CN109265556A (zh) 一种适用于静脉、腹腔或鼻腔给药的多肽
EP2990415B1 (en) Cyclic beta defensins analogs for the treatment of infections
US20180201647A1 (en) Peptoid
WO2017149098A1 (en) Fusion respiratory syncytial virus inhibitors and use thereof
CN111247162B (zh) 多黏菌素类似物及其制备方法
JPWO2018038168A1 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
JP2014198711A (ja) Ct阻害4価ペプチドおよびコレラ治療薬
US12012440B2 (en) Compositions and methods for treatment of fungal infections
WO1997048725A1 (en) Novel peptides for prevention and treatment of infection
TW476650B (en) Use of a cytokine regulatory agent to treat rheumatoid arthritis
JPWO2008050830A1 (ja) 抗hiv剤